Targeting a Fibrotic Bottleneck May Provide an Opening in the Treatment of LUTS
Studysummary This paper discusses the potential of targeting fibrosis in addressing lower urinary tract symptoms associated with benign prostatic hyperplasia, but it provides no new clinical findings and highlights the need for further research.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The editorial discussed the role of fibrosis in benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), noting that current treatments are ineffective against fibrosis, which worsens urinary dysfunction. The authors emphasized the need for new antifibrotic treatments and advanced diagnostic tools to address inflammation-driven fibrosis in BPH/LUTS, and highlighted the importance of animal models for studying these mechanisms and testing therapies.
